S M Gadalla1, R M Pfeiffer2, S Y Kristinsson3,4, M Björkholm3, O Landgren5, M H Greene1. 1. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA. 2. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA. 3. Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden. 4. Faculty of Medicine, University of Iceland and Department of Hematology, Landspitali National University Hospital, Reykjavik, Iceland. 5. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND AND PURPOSE: Patients with myotonic dystrophy (DM) are at high risk of brain cancer. This study describes the spectrum of brain neoplasms in DM patients. METHODS: Data from 1119 DM patients identified from the National Swedish Patient Register between 1987 and 2007 were linked to the National Cancer and the Cause of Death Registers. Standardized incidence ratios (SIRs) and cumulative incidence to quantify the relative and absolute risks of brain neoplasms were calculated and the Kaplan-Meier estimator was used for survival analysis. Patient follow-up started at birth or the age at the start of Swedish cancer registration (1 January 1958) and ended at the age of brain neoplasm diagnosis, death or on 31 December 2007. RESULTS: Twenty patients developed brain neoplasm during follow-up {median age 53, range 2-76 years, accounting for a five-fold excess risk of brain tumors during the patient lifetime [SIR = 5.4, 95% confidence interval (CI) 3.4-8.1, P = 1 × 10(-5) ]}. Astrocytoma was the most common histological subtype (n = 16, 80%), and almost all cases (n = 19) developed after age 20. No statistically significant differences in gender-specific risks (SIR in men 6.3 and in women 3.8, P-heterogeneity 0.46) were observed. After accounting for competing mortality related to DM, the cumulative incidence of brain neoplasms reached 2.9% (95% CI 1.8%-4.7%) by age 70. Five-year survival after brain tumor diagnosis was 52% (95%CI 29%-75%) overall (number at risk 8) and 34% (95% CI 26%-47%) for malignant neoplasms (number at risk 5). CONCLUSION: Despite the high relative risk of DM-related brain tumors, the absolute risk is modest. Nonetheless, careful evaluation of DM patients with new central nervous system symptoms is warranted. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND AND PURPOSE: Patients with myotonic dystrophy (DM) are at high risk of brain cancer. This study describes the spectrum of brain neoplasms in DM patients. METHODS: Data from 1119 DM patients identified from the National Swedish Patient Register between 1987 and 2007 were linked to the National Cancer and the Cause of Death Registers. Standardized incidence ratios (SIRs) and cumulative incidence to quantify the relative and absolute risks of brain neoplasms were calculated and the Kaplan-Meier estimator was used for survival analysis. Patient follow-up started at birth or the age at the start of Swedish cancer registration (1 January 1958) and ended at the age of brain neoplasm diagnosis, death or on 31 December 2007. RESULTS: Twenty patients developed brain neoplasm during follow-up {median age 53, range 2-76 years, accounting for a five-fold excess risk of brain tumors during the patient lifetime [SIR = 5.4, 95% confidence interval (CI) 3.4-8.1, P = 1 × 10(-5) ]}. Astrocytoma was the most common histological subtype (n = 16, 80%), and almost all cases (n = 19) developed after age 20. No statistically significant differences in gender-specific risks (SIR in men 6.3 and in women 3.8, P-heterogeneity 0.46) were observed. After accounting for competing mortality related to DM, the cumulative incidence of brain neoplasms reached 2.9% (95% CI 1.8%-4.7%) by age 70. Five-year survival after brain tumor diagnosis was 52% (95%CI 29%-75%) overall (number at risk 8) and 34% (95% CI 26%-47%) for malignant neoplasms (number at risk 5). CONCLUSION: Despite the high relative risk of DM-related brain tumors, the absolute risk is modest. Nonetheless, careful evaluation of DM patients with new central nervous system symptoms is warranted. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
Authors: G Meola; V Sansone; D Perani; A Colleluori; S Cappa; M Cotelli; F Fazio; C A Thornton; R T Moxley Journal: Neurology Date: 1999-09-22 Impact factor: 9.910
Authors: C L Liquori; K Ricker; M L Moseley; J F Jacobsen; W Kress; S L Naylor; J W Day; L P Ranum Journal: Science Date: 2001-08-03 Impact factor: 47.728
Authors: G Antonini; C Mainero; A Romano; F Giubilei; V Ceschin; F Gragnani; S Morino; M Fiorelli; F Soscia; A Di Pasquale; F Caramia Journal: J Neurol Neurosurg Psychiatry Date: 2004-11 Impact factor: 10.154
Authors: Alfonso Di Costanzo; Francesco Di Salle; Lucio Santoro; Alessandro Tessitore; Vincenzo Bonavita; Gioacchino Tedeschi Journal: J Neurol Date: 2002-09 Impact factor: 4.849
Authors: M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy Journal: Science Date: 1992-03-06 Impact factor: 47.728
Authors: Y H Fu; A Pizzuti; R G Fenwick; J King; S Rajnarayan; P W Dunne; J Dubel; G A Nasser; T Ashizawa; P de Jong Journal: Science Date: 1992-03-06 Impact factor: 47.728
Authors: J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson Journal: Cell Date: 1992-02-21 Impact factor: 41.582
Authors: Jose I Emparanza; Adolfo López de Munain; Mark H Greene; Ander Matheu; Roberto Fernández-Torrón; Shahinaz M Gadalla Journal: Muscle Nerve Date: 2018-10 Impact factor: 3.217
Authors: Andrea Mignarri; Francesco Gentili; Francesco Masia; Angelo Genua; Silvia Cenciarelli; Paola Brunori; Maria Antonietta Mazzei; Alessandro Malandrini; Antonio Federico; Francesco Giuseppe Mazzei; Maria Teresa Dotti Journal: Neurol Sci Date: 2017-11-25 Impact factor: 3.307
Authors: A F Best; J E Hilbert; L Wood; W B Martens; N Nikolenko; C Marini-Bettolo; H Lochmüller; P S Rosenberg; R T Moxley; M H Greene; S M Gadalla Journal: Eur J Neurol Date: 2018-09-16 Impact factor: 6.089
Authors: Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla Journal: Int J Cancer Date: 2017-11-20 Impact factor: 7.396
Authors: Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla Journal: JNCI Cancer Spectr Date: 2018-12-10
Authors: Ewan Gray; Holly J Butler; Ruth Board; Paul M Brennan; Anthony J Chalmers; Timothy Dawson; John Goodden; Willie Hamilton; Mark G Hegarty; Allan James; Michael D Jenkinson; David Kernick; Elvira Lekka; Laurent J Livermore; Samantha J Mills; Kevin O'Neill; David S Palmer; Babar Vaqas; Matthew J Baker Journal: BMJ Open Date: 2018-05-24 Impact factor: 2.692